Cookie Policy

A full description of our cookie policy can be found here.

Essential (Required)

Cookies that the site cannot function without. This includes cookies for access to secure areas and CSRF protection. Please note that Craft's default cookies do not collect any personal or sensitive information. Craft's default cookies do not collect IP addresses. The information they store is not sent to Pixel & Tonic or any 3rd parties.

Name: CraftSessionId
Description: Craft relies on PHP sessions to maintain sessions across web requests. That is done via the PHP session cookie. Craft names that cookie “CraftSessionId” by default, but it can be renamed via the phpSessionName config setting. This cookie will expire as soon as the session expires.
Provider: biocatalysts.com
Expiry: Session

Name: *_identity
Description: When you log into the control panel, you’ll get an authentication cookie used to maintain your authenticated state. The cookie name is prefixed with a long, randomly generated string, followed by _identity. The cookie only stores information necessary to maintain a secure, authenticated session and will only exist for as long as the user is authenticated in Craft.
Provider: biocatalysts.com
Expiry: Persistent

Name: *_username
Description: If you check the "Keep me logged in" option during login, this cookie is used to remember the username for your next authentication.
Provider: biocatalysts.com
Expiry: Persistent

Name: CRAFT_CSRF_TOKEN
Description: Protects us and you as a user against Cross-Site Request Forgery attacks.
Provider: biocatalysts.com
Expiry: Session

BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects

Published 15 January 2025

Home/ Media & Resources/ Annual Report 2023/24: BRAIN Biotech AG acts from a strong cash position and is confident about its growth prospects

Group cash and cash equivalents improved to € 27.2 million
Successfully closed two milestone transactions with Royalty Pharma and Akribion Therapeutics
Management sees a strong start to the new financial year
Updated mid-term targets at the CMD 2024 and well-founded optimism for new business year 2024/25

BRAIN Biotech AG, a leading provider of speciality enzymes and innovative biosolutions for industry, has announced its financial results for the 2023/24 fiscal year. The Group’s cash reserves have grown significantly, reaching a robust €27.2 million. Over the past year, the company achieved two major milestones: a royalty monetisation agreement with Royalty Pharma, with potential milestone payments of up to €128.88 million, and an exclusive pharmaceutical licensing deal with Akribion Therapeutics, offering up to €92.3 million in milestone payments plus royalties on net sales. Consolidated revenue for the fiscal year remained stable at €54.6 million.

Outlook for 2025

For the 2024/25 fiscal year, BRAIN Biotech anticipates accelerating revenue growth in line with its mid-term growth projections. Adjusted EBITDA is expected to increase at a rate exceeding sales growth. Consistent with its strategic priorities, the company will continue exploring bolt-on acquisitions to enhance product expertise and further drive growth.

“

We have a good and solid foundation on which to build, our markets are large and attractive, and we have the tools to succeed

— Adriaan Moelker, CEO BRAIN Biotech AG